News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Vincristine, ACNU, Carboplatin and Interferon Beta with Radiation (VAC-FERON-R) for Newly Diagnosed Glioblastoma Multiforme


Posted on: 11/17/2003

15th International Conference on Brain Tumor Research and Therapy. Sorrento, Italy. May 24–27, 2003. Abstract No. 3 Neuro-Oncology, Volume 5, Issue 4, October 2003

Vincristine, ACNU, Carboplatin and Interferon Beta with Radiation (VAC-FERON-R) for Newly Diagnosed Glioblastoma Multiforme

Tomokazu Aoki, Tetsuya Ueba, Jun Takahashi, Natstuo Ooya, Masahiro Hiraoka, Masatsune Ishikwa, and Nobuo Hashimoto

Kyoto Neuro-Oncology Group, Kitno Hospital, Osaka, Japan; Faculty of Medicine, Kyoto University, Kyoto, Japan

Purpose. Novel combination therapies are needed for patients with newly diagnosed glioblastoma multiforme. From reports on meta-analysis, we selected 4 drugs (vincristine, ACNU, carboplatin, and interferon beta [IFN-β]). This phase II study was performed to determine the safety, tolerability, and efficiency of this therapy.

Patients and Methods. Forty-one patients were enrolled onto this open-label, phase II study. ACNU (60 mg/m2), carboplatin (110 mg/m2), vincristine (0.6 mg/m2), and interferon (300 million/body) were administered in day 1, concomitant with fractionated radiotherapy (63 Gy total dose: 1.8 Gy × 5 days for 7 cycles), and vincristine ( 0.6 mg/m2) and interferon (300 million/body) were administered in days 7 and 15; IFN-β (300 million/body) was administered 3 times for a week during the radiation course. Two months after the radiation, ACNU (60 mg/m2), carboplatin (110 mg/m2), vincristine (0.6 mg/m2), and interferon β (300 million/body) were administered in day 1, and vincristine (0.6 mg/m2) and interferon β (300 million/body) were administered in days 7 and 15, every 58 days. The primary end points were safety and tolerability, and the secondary end point was overall survival.

Results. VAC-feron-R was safe and well tolerated. Nonhematologic toxicities were rare and mild to moderate in severity. During the concomitant treatment phase, grade 3 neurocytopenia, thrombocytopenia, or both were observed in 23% of patients. Grade 4 hematological toxicities were not observed. During adjuvant chemotherapy after radiation, 3% cycles were associated with grade 3 neutropenia or thrombocytopenia. None of the cycles were associated with grade 4 toxicities. Time to progression was 8 months. Median survival was 16 months.

Conclusion. VAC-feron-R is safe and well tolerated. This regimen of concomitant chemoradiationtherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma multiforme. Further investigation is warranted.

Copyright © 2003 by the Society for Neuro-Oncology

Source: http://ninetta.ingentaselect.com/vl=8274130/cl=50/nw=1/rpsv/cw/dup/15228517/previews/031005


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740